Pharmaceutical companies are currently evaluating FGFR1 agonists and FGF21 analogous for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH), which have been shown to reduce body weight, improve lipid profiles, reduce liver fat content, and reduce liver fibrosis in individuals with NASH, and resolve NASH in clinical trials.76 This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.